![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, April 26, 2019 9:16:35 AM
Recent MBRX News
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/15/2024 01:57:37 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 12:05:24 PM
- Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 08/14/2024 12:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:00:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 01:10:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 01:05:10 PM
- Moleculin to Host Webcast Presentation to Discuss Recently Announced Plans for MIRACLE Phase 3 Pivotal Trial Tuesday, August 6, 2024 at 8:30 AM ET • PR Newswire (US) • 08/05/2024 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 12:35:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 12:30:17 PM
- Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial • PR Newswire (US) • 08/01/2024 12:30:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/30/2024 11:00:46 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 07/22/2024 09:31:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/10/2024 12:30:31 PM
- Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML • PR Newswire (US) • 07/10/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/18/2024 09:00:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 12:00:40 PM
- Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial • PR Newswire (US) • 06/14/2024 12:00:00 PM
- Moleculin to Present at the Virtual Investor Pitch Conference • PR Newswire (US) • 06/12/2024 01:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 06/07/2024 09:05:48 PM
- Moleculin to Participate in the Virtual Investor Lunch Break Series • PR Newswire (US) • 06/05/2024 12:55:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/16/2024 12:32:14 PM
- Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress • PR Newswire (US) • 05/16/2024 12:32:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 12:38:16 PM
- Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06) • PR Newswire (US) • 05/15/2024 12:38:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:16:53 PM
FEATURED POET Technologies Reports Second Quarter 2024 Financial Results • Aug 15, 2024 8:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
ATWEC Reaches Profitability, Announces Massive Earnings Growth, and a Strong Forecast for the Rest of 2024 • ATWT • Aug 15, 2024 7:16 AM
Alliance Creative Group (ACGX) Releases Q2 2024 Financial and Disclosure Report with an increase of over $130,000 in Net Income from Q2 2023 to Q2 2024 • ACGX • Aug 14, 2024 8:30 AM
Avant Technologies Unveils AI-Powered Healthcare Infrastructure to Deliver Intelligent Healthcare Solutions • AVAI • Aug 14, 2024 8:00 AM
SANUWAVE Announces Record Quarterly Revenues: Q2 FY2024 Financial Results • SNWV • Aug 13, 2024 7:11 AM